Voices
Agenus
Agenus/LinkedIn

New Data Published in JITC Show BOT+BAL Deliver Durable Responses in Platinum-Refractory Ovarian Cancer – Agenus

Agenus shared a post on LinkedIn about a recent article by Rebecca Porter et al, published in The Journal for ImmunoTherapy of Cancer:

“New data published in JITC show botensilimab + balstilimab (BOT+BAL) delivering deep and durable responses in women with heavily pretreated, platinum-refractory ovarian cancer—an area with few remaining options.

These findings underscore the potential of Fc-enhanced CTLA-4 + PD-1 blockade to activate meaningful immune responses in tumors long considered resistant to immunotherapy.

Read the release”

Title: Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer

Authors: Rebecca Porter, Bruno Bockorny, Bradley R. Corr, Daruka Mahadevan, Breelyn A. Wilky, Anthony B. El-Khoueiry, Andrea J. Bullock, Navid Hafez, Justin Moser, Anastasia Martynova, Justin Stebbing, Bishnu Joshi, Sean Bourdelais, Chloe Delepine, Dhan Chand, Wei Wu, Benny Johnson, Joseph E. Grossman, Steven J. O’Day, Ursula A. Matulonis, Michael S. Gordon

Read the Full Article on The Journal for ImmunoTherapy of Cancer

New Data Published in JITC Show BOT+BAL Deliver Durable Responses in Platinum-Refractory Ovarian Cancer - Agenus

More posts about Agenus.

Agenus Anastasia Martynova Andrea J. Bullock Anthony B. El-Khoueiry Balstilimab Benny Johnson Bishnu Joshi botensilimab Bradley R. Corr Breelyn A. Wilky Bruno Bockorny cancer Chloe Delepine Daruka Mahadevan Dhan Chand Joseph E. Grossman Justin Moser Justin Stebbing Michael S. Gordon Navid Hafez OncoDaily Oncology Ovarian Cancer Rebecca Porter Sean Bourdelais Steven J. O’Day Ursula A. Matulonis Wei Wu